Company Filing History:
2 out of 15 
1 out of 93 
Years Active: 2024
Title: Innovator Spotlight: YoungKwang Kim from Seongnam-Si, KR
Introduction
YoungKwang Kim is a distinguished inventor based in Seongnam-Si, South Korea. He has made significant contributions to the field of biomedical science, particularly through his innovative developments in bispecific antibodies. With a total of two patents to his name, his work is paving the way for new treatments in cancer therapy.
Latest Patents
Among YoungKwang Kim’s recent patents is the "Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof." This groundbreaking invention focuses on an antibody capable of effectively blocking the interactions between PD-L1 and its receptor PD-1, as well as between LAG3 and its ligand. The bispecific antibody exhibits a high binding affinity for both human PD-L1 and LAG3 proteins, along with providing additional specificity for other antigens.
Another noteworthy patent is the "Anti-EGFR/anti-4-1BB bispecific antibody." This invention comprises a pharmaceutical composition and method aimed at treating or preventing cancer. Through these innovative solutions, YoungKwang Kim aims to enhance therapeutic options for patients battling cancer.
Career Highlights
YoungKwang Kim has honed his expertise while working with reputable companies such as Abl Bio Inc. and Yuhan Corporation. His tenure at these organizations has not only enriched his knowledge but has also expanded his impact on the field of biotechnology and pharmaceuticals.
Collaborations
Throughout his career, YoungKwang has collaborated with several professionals, including Yangsoon Lee and Youngdon Pak. These collaborations have fostered a productive environment for research and innovation, allowing for the sharing of ideas and expertise that can lead to further advancements in healthcare solutions.
Conclusion
In conclusion, YoungKwang Kim stands out as a remarkable inventor whose work in bispecific antibodies represents a significant leap forward in cancer treatment. With his extensive background and fruitful collaborations, he continues to contribute to the advancement of medical science, positioning himself as a leader in innovations that enhance patient outcomes.